<DOC>
	<DOCNO>NCT02126839</DOCNO>
	<brief_summary>The study evaluate chronic-dose efficacy safety Albuterol MDPI compare placebo pediatric participant asthma .</brief_summary>
	<brief_title>A Chronic-Dose Safety Efficacy Study Albuterol Multi-Dose Dry Powder Inhaler Pediatric Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Albuterol</mesh_term>
	<criteria>1 . Written inform consent/assent sign dated patient and/or parent/caregiver/legal guardian ( appropriate ) conduct study related procedure 2 . Male premenarchal female 411 year age , inclusive , screen visit ( SV ) 3 . Has document physician diagnosis asthma per EPR3 Guidelines minimum 6 month duration stable least 4 week prior SV 4 . Has ability perform spirometry reproducibly consistent ATS guideline protocolspecific guideline 5 . Has FEV1 5095 % predict age , height gender SV follow minimum 6hour period without β2agonist use . ( Note : Predicted value 49.5049.99 % may round 50 % value 95.0195.49 % may round 95 % . ) 6 . Demonstrated reversible bronchoconstriction verify 15 % great increase baseline FEV1 within 30 minute follow inhalation 180 mcg albuterol . ( Note : Reversibility value 14.5014.99 % may round 15 % . ) 7 . Is maintain lowdose inhaled corticosteroid ( ICS , less equal 200 mcg fluticasone propionate per day equivalent ) , leukotriene modifier ( LTM ) , inhaled cromones , and/or shortacting β2agonists ( SABA ) ; need SABA alone acceptable . The ICS , LTM , cromone dos must stable least 4 week prior SV maintain duration study 8 . Can selfperform peak expiratory flow rate ( PEF ) measurement handheld peak flow meter 9 . Can tolerate withdrawal applicable medication qualification screen 10 . Otherwise general good health , define free concomitant condition treatment could interfere study conduct , influence interpretation study observations/results , put patient increase risk trial , clinically acceptable 6month medical history , physical examination , 12lead electrocardiogram ( ECG ) , vital sign 11 . Parents consent capable understanding requirement , risk benefit study participation , , judge investigator , capable give informed consent compliant study requirement ( eg , visit , recordkeeping ) 12 . The patient able correctly use MDPI device , either alone assistance parent/guardian . Exclusion Criteria 1 . Known hypersensitivity albuterol excipients inhaler formulation ( eg , lactose , ethanol ) 2 . Participation ( receive study medication ) investigational drug trial within 30 day precede SV plan participation another investigational drug trial time trial 3 . History severe milk protein allergy 4 . History respiratory infection disorder ( include , limited bronchitis , pneumonia , acute chronic sinusitis , otitis medium , influenza ) resolve within 4 week precede SV 5 . Any asthma exacerbation require oral corticosteroid within 3 month SV . A patient must hospitalization asthma within 6 month prior SV . 6 . Initiation immunotherapy study period dose escalation study period . Patients treat immunotherapy prior SV must use stable ( maintenance ) dose ( 90 day ) consider inclusion . 7 . History lifethreatening asthma define protocol asthma episode require intubation and/or associate hypercapnea , respiratory arrest , hypoxic seizure 8 . Use prohibit concomitant medication within washout prescribe per protocol prior study visit 9 . Use medication asthma allergic rhinitis prohibit per protocol describe protocol 10 . The dosage require LTM , ICS , inhale cromones , stable least 4 week . Intranasal corticosteroid and/or cromones stable least two week prior SV . Allowed corticosteroid , LTM , cromone asthma allergy medication continue dos conduct study . 11 . Presence nonasthmatic acute chronic condition , include limited bronchitis , emphysema , active tuberculosis , bronchiectasis , cystic fibrosis , clinically significant cardiovascular disease ( include limit cardiac arrhythmia uncontrolled hypertension ) , clinically significant hepatic , renal , endocrine dysfunction , stroke , uncontrolled diabetes mellitus , hyperthyroidism , convulsive disorder , malignancy basal cell carcinoma . Significant define condition , opinion investigator , would put safety patient risk participation , could affect safety efficacy analyse 12 . Any medical psychological condition investigator 's opinion preclude study enrollment 13 . Previous participation ( receive MDPI study medication ) Albuterol MDPI study 14 . Study participation clinical investigator site employee and/or immediate relative 15 . Study participation relate nonrelated individual live household , ie , one subject per household may participate study time . 16 . Require continuous treatment βblockers , MAO inhibitor , tricyclic antidepressant , anticholinergic , and/or systemic corticosteroid 17 . Treated oral injectable corticosteroid within 6 week prior SV 18 . Hospitalization acute asthma exacerbation &gt; 2 time 12 month prior screen and/or received emergency room treatment nebulized albuterol hospitalize asthma exacerbation within 6 month prior SV</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>